OPEN END TURBO PUT-OPTIONSSCHEIN MIT SL - AMGEN | Real-time Boerse Frankfurt Warrants 12:57:05 2024-07-05 EDT | ||
| 14.73 EUR | -1.14% |
|
| Current month | +0.68% | ||
| 1 month | -0.33% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
| Date | Price | Change |
|---|---|---|
| 24-07-05 | 14.73 | -1.14% |
| 24-07-04 | 14.9 | -0.07% |
| 24-07-03 | 14.91 | +0.68% |
| 24-07-02 | 14.81 | -0.47% |
| 24-07-01 | 14.88 | +0.54% |
Real-time Boerse Frankfurt Warrants
Last update July 05, 2024 at 12:57 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | AMGEN INC. |
| Issuer | 
Société Générale
|
| WKN | SU6XB9 |
| ISIN | DE000SU6XB90 |
| Date issued | 2024-01-12 |
| Strike | 470.7 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 15.35 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 19.72 € |
|---|---|
| Lowest since issue | 13.49 € |
| Spread | 0.05 € |
| Spread % | 0.34% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
309.4
USD
Average target price
316.4
USD
Spread / Average Target
+2.28%
- Stock Market
- Certificates
- Certificat
